Ulcerative Colitis Clinical Trial
Official title:
Randomized Controlled Trial of High Definition White Light Endoscopy Versus Chromoendoscopy for Dysplasia Detection in Ulcerative Colitis Surveillance
Verified date | August 2019 |
Source | The Leeds Teaching Hospitals NHS Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Patients with ulcerative colitis (UC) have an increased risk for colorectal cancer (CRC)
compared to the general population. Regular screening by colonoscopy is an internationally
recommended cancer prevention strategy. Random sampling of the mucosa throughout the colon
has been the mainstay of conventional surveillance practice to detect abnormalities, known as
dysplasia which can progress to CRC. This requires multiple biopsies, to be taken and
processed, a practice which is is tedious, expensive, time consuming and has a low pickup
rate. Dysplasia in UC is typically flat and patchy and can be easily overlooked with standard
conventional white light colonoscopy (WLC).
Detection can be improved by the application of dyes which highlight more subtle
abnormalities. This practice, known as chromoendoscopy (CE) is better than WLC at dysplasia
detection but more time consuming for the patient and cannot guarantee that the whole colon
is covered. CE has only been compared in clinical trials with standard definition endoscopy
rather than the recently available high definition endoscopes with better resolution and
picture. High definition (HD) endoscopy uses a high definition onitor and a high resolution
CCD (charge coupled device) providing much better images than standard video endoscopy. HD
colonoscopy promises therefore to provide an alternative to CE in UC surveillance without the
need for the extra time and experience required for dye spraying for both endoscopists and
nursing staff.
The investigators plan to do a randomized trial to assess HD colonoscopy alone compared to
chromoendoscopy (with HD colonoscopies) for dysplasia detection during surveillance for
ulcerative colitis. There have been no trials comparing these two modalities and the
investigators hope to provide evidence that the additional benefit of CE over HD colonoscopy
would be marginal and therefore CE would be reserved for procedures using standard definition
scopes.
Status | Completed |
Enrollment | 152 |
Est. completion date | September 19, 2015 |
Est. primary completion date | September 19, 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility |
Inclusion Criteria: - Patients with longstanding (more than 10 years), extensive (extending proximal to the splenic flexure) colitis attending for surveillance colonoscopy. - Patients over 18 years of age Exclusion Criteria: - Pregnancy - Unwilling or unable to give informed consent - Severe active colitis (as assessed by the endoscopist) |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Leeds Teaching Hospitals NHS Trust | Leeds | West Yorkshire |
Lead Sponsor | Collaborator |
---|---|
The Leeds Teaching Hospitals NHS Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | number of lesions | The number of lesions with at least low grade dysplasia detected by targeted biopsy to be compared between the two groups by chisquared test. | Once annually at routine clinical assessment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |